- Brodalumab is associated with superior efficacy for moderate to severe plaque psoriasis compared with etanercept, adalimumab, ustekinumab, secukinumab, and guselkumab, according to a network meta-analysis from Canada.
Why this matters
- Many new biologic therapies have recently become available for treatment of psoriasis, but head-to-head trials are lacking.
- Brodalumab 210 mg was associated with superior efficacy (rate of 100% improvement in the Psoriasis Area and Severity Index [PASI 100]) compared with (relative risks; 95% credible intervals):
- Placebo: 496.1 (332.1-768.5).
- Ustekinumab 45 mg: 2.29 (1.86-2.88).
- Ustekinumab 90 mg: 1.85 (1.45-2.48).
- Secukinumab 300 mg: 1.41 (1.1-1.87).
- Etanercept 50 mg: 5.43 (4.08-7.51).
- Adalimumab 80 mg/40 mg: 3.48 (2.52-5).
- Guselkumab 100 mg: 1.48 (1.09-2.08).
- Results were not statistically significant for infliximab 5 mg/kg (1.24; 0.93-1.7) or ixekizumab 160 mg/80 mg (0.97; 0.79-1.23).
- Similar results were observed for PASI 75 and PASI 90.
- 43 randomized controlled trials were included in the meta-analysis.
- Funding: Bausch Health, Canada Inc. (manufacturer of brodalumab).
- No comparison of safety data.